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Abstract
Introduction
From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with
4,107 notifications. The most serious complication of Q-fever is chronic Q-fever.
Method
In 2014, we contacted all 2,161 adult inhabitants of the first village in the Netherlands
affected by the Q-fever epidemic and offered to test for antibodies against Coxiella burnetii
using immunofluorescence assay (IFA) to screen for chronic infections and assess whether
large-scale population screening elsewhere is warranted.
Results
Of the 1,517 participants, 33.8% were IFA-positive. Six IFA-positive participants had an IgG
phase I titer1:512. Two of these six participants were previously diagnosed with chronic
Q-fever. Chronic infection was diagnosed in one of the other four participants after clinical
examination.
Conclusions
Seven years after the initial outbreak, seroprevalence remains high, but the yield of screen-
ing the general population for chronic Q-fever is low. A policy of screening known high-risk
groups for chronic Q-fever in outbreak areas directly following an outbreak might be more
efficient than population screening. A cost-effectiveness analysis should also be performed
before initiating a population screening program for chronic Q-fever.
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Introduction
Q-fever is a zoonotic disease caused by the bacterial pathogen Coxiella burnetii (C. burnetii)
[1,2]. From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with
4,107 notifications [3]. Prior to 2007, the seroprevalence of Q-fever antibodies among the
Dutch general population was 2.4% [3]. In 2007, a sample of the inhabitants of Herpen—the
first Dutch village affected by the Q-fever outbreak—had a seroprevalence rate of 25.1% [4].
The most serious complication of Q-fever is chronic Q-fever. Chronic Q-fever develops in
1.5–2% of Q-fever infections and can be detected months—or even years—after the initial
infection, which was either symptomatic or asymptomatic [5]. The risk factors for chronic
Q-fever include pre-existing cardiac valvulopathy, vascular graft, aneurysm, and immunosup-
pression [5]. Chronic C. burnetii infection can lead to endocarditis, an infected aneurysm or
vascular graft, causing high morbidity and mortality even if optimal treatment is received [1,6].
Because chronic Q-fever is not classified as a notifiable disease, precise numbers are not avail-
able; however, up to May 2012, 284 patients were voluntarily registered into a database as part
of a research project run by the University Medical Center Utrecht [7]. For early detection of
chronic Q-fever, patients should have at least one serological examination within one year fol-
lowing the acute infection [8]. The serological follow-up screening of acute Q-fever patients
varies widely among regions, ranging from 25% to 95% [9].
General practitioners (GPs), inhabitants of regions with a high Q-fever incidence and the
Dutch national Q-fever patient organization, speculated that the number of chronic Q-fever
cases of the 2007–2010 epidemic was underestimated. Chronic Q-fever was incidentally diag-
nosed years after asymptomatic infection but the extent was never quantified. Therefore, seven
years after the initial outbreak in the Netherlands, we measured the serological C. burnetii sta-
tus of inhabitants of the high incidence village Herpen in order to identify chronic Q-fever
infections and assess whether large-scale population screening elsewhere is warranted.
Methods
The Municipal Health Service (MHS) “GGD Hart voor Brabant” performed this study as part
of the larger Q Herpen II project. The Medical Ethics Review Committee of the University
Medical Center Utrecht approved the study (protocol 13-367/D Q Herpen II).
For this cross-sectional population study, all adult inhabitants (18 years of age) of the village
of Herpen (Dutch postal code 5373) were invited to participate. The municipal administration
provided demographic data for these 2,161 inhabitants. In January 2014, all inhabitants were sent
an information package by post, including information regarding the study, a request to partici-
pate, a questionnaire, an informed consent form, and a laboratory form for venipuncture.
The questionnaire included questions regarding demographics, smoking history, risk factors
associated with chronic Q-fever, history of Q-fever infection and vaccination. Answers to ques-
tions about general health status, initial symptoms, chronic medical conditions, and medica-
tion use are currently being analyzed in other sub-studies.
During five days in February and one day in March 2014, participants provided their writ-
ten informed consent to participate in this study with the questionnaire. Informed consent
forms and questionnaires were checked for missing information and errors by medical staff
and the participant, followed by a venipuncture.
Diagnosis
Antibodies against C. burnetii were measured using immunofluorescence assay (IFA) see Sup-
plementary Information (SI) S1 Text, and an IgG phase I or II titer1:64 was interpreted as
IFA-positive.
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The Dutch Q-fever Consensus Group [10] considers an IgG phase I titer1:1024 an indica-
tion of possible chronic Q-fever; for a definitive diagnosis, a comprehensive medical examina-
tion is required. In our study, given the lack of an initial clinical examination, the serological
cut-off value was set one dilution lower (at IgG phase I 1:512) in order to maximize sensitivity.
Participants with an IgG phase I titer1:512 were tested further using the Q-fever polymer-
ase chain reaction test (PCR) S1 Text, and referred to the Q-fever clinic at Radboud university
medical center (Radboudumc) for clinical examination, including echocardiography and posi-
tron emission tomography-computed tomography (PET-CT) [10], when deemed necessary.
The IFA results were reported to the participants and their GP together with a medical
recommendation.
Previous infections
The IFA test results of this study in 2014 were compared with those obtained in 2007. The
2007 and 2014 studies were performed in the same village (Herpen) and used the same labora-
tory tests and cut-off values [4]. Data regarding previous Q-fever infections and notifications
were obtained from the MHS.
Data analysis
Questionnaires were digitally scanned and analyzed using SPSS 21.0. The age and gender of the
non-responders were obtained from the municipal administration data. Proportions were
compared using the chi-square test. Differences with p<0.05 were considered to be significant
(two-tailed analysis). The independent sample t-test was used to calculate means.
Results
The study population
Both a blood sample and a completed questionnaire were provided by 70.2% (N = 1,517/2,161)
of the adult inhabitants of Herpen, the Netherlands. The characteristics of the participants are
summarized in Table 1.
Participants and non-participants were similar with respect to age (p = 0.31) and
gender (p = 0.35). The mean age of the participants and non-participants was 51.9 years (SD:
16.5 years) and 51.2 years (SD: 21.9 years), respectively. More participants with Q-fever
(N = 51/1,517) were notified by the MHS compared to non-participants with Q-fever (N = 2/
644; p<0.01).
Prevalence of antibodies against C. burnetii. Of the 1,517 participants, 513 (33.8%) tested
positive for antibodies against C. burnetii (i.e., were IFA-positive; for titers see S1 Table). Three
of the 513 IFA-positive participants became seropositive after receiving a Q-fever vaccination
in 2011; two other vaccinated participants were seronegative in 2014. The IFA-positive and
IFA-negative participants were similar with respect to age, gender and education level. A risk
factor for being IFA-positive was current smoking (OR 1.4; 95% CI: 1.05–1.80; p = 0.02) versus
former smoker and never smoked.
Of the 513 IFA-positive participants, six (1.2%) had an IgG I1:512, Table 2 and a
negative Q-fever PCR test. Two of these six participants were diagnosed previously with
chronic Q-fever. The remaining four (two with an IgG phase I 1: 512) were referred for a com-
prehensive clinical examination; three of these participants had no evidence of a chronic C.
burnetii infection and one participant-a male over the age of 65, with an increased erythrocyte
sedimentation rate and a history of renal insufficiency, and diabetes mellitus type 2- was diag-
nosed with chronic Q-fever. This participant presented with a cardiac murmur, and although
Population Screening for Chronic Q-Fever
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Table 1. Characteristics of the study participants.
All IFA-Positive IFA-negative
N = 1,517 (100%) N = 513 (33.8%) N = 1,004 (66.2%) p-value
Mean age, years1 51.9 (SD 16.5) 51.6 (SD 15.7) 52.1 (SD 16.9) 0.58
Gender2 0.70
Male 752 (49.6) 258 (50.3) 494 (50.8)
Female 765 (50.4) 255 (49.7) 510 (49.2)
Smoking2 0.02
Current 276 (18.3) 110 (21.4) 166 (16.6)
Former 570 (37.7) 194 (37.8) 376 (37.6)
Never 666 (44.0) 209 (40.8) 457 (45.8)
Education level2,3 0.25
Low 825 (55.2) 290 (57.3) 535 (54.1)
Average 425 (28.4) 149 (29.4) 276 (27.9)
High 245 (16.4) 67 (13.2) 178 (18.0)
All cardiovascular risk factors4 93 22 71
One or more cardiovascular risk factors 69 16 53
Aneurysm 19 (20.4) 8 (36.4) 11 (15.5)
Aortic bifurcation prosthesis 2 (2.2) 0 (0.0) 2 (2.8)
Stent graft 40 (43.0) 6 (27.3) 34 (47.9)
Tube graft 1 (1.1) 1 (4.5) 0 (0.0)
Bypass 20 (21.5) 3 (13.6) 17 (23.9)
Heart valve surgery 11 (11.8) 4 (18.2) 7 (9.9)
1Independent sample t-test
2Pearson’s chi-square test. For the purpose of the analysis current smoking was compared with past and never smoked and for education level low was
compared with average combined with high.
3Education level: low, ranging from no education to vocational training; average, ranging from secondary vocational education to preparatory academic
training and high, higher professional and/or university education.
4The p-value was not calculated for this heterogeneous group
doi:10.1371/journal.pone.0131777.t001
Table 2. Summary of the six participants with an IgG I titre1:512 and Q-fever status after clinical examination.
Patient IgG phase
I
IgG phase
II
Gender Age* Initial
symptoms
Year diagnosis Q-
fever
Underlying disease Chronic Q-fever
diagnosed
1 1:512 1:4096 female <65 yes 2007 None no
2 1:512 1:4096 male <65 no 2014 None no
3 1:1024 1:1024 female 65 no 2014 Diabetes mellitus type
II
no
4 1:1024 1:2048 male 65 yes 2008 Aneurysm + stent yes, 2008
5 1:1024 1:2048 male 65 yes 2010 Heart valve surgery yes, 2011
6 1:1024 1:4096 male 65 no 2014 Diabetes mellitus type
II
yes, 2014
Impaired renal
function
*The age is not shown as the exact age of the participant as this could compromise the privacy of the individual. Participants 1, 2,3, and 6 were due this
study referred for a comprehensive clinical examination to exclude chronic Q-fever. Participants number 4, 5 and 6 were diagnosed with chronic Q-fever;
number 4 after the development of an aneurysm, number 5 during screening before vaccination of high risk groups and, number 6 as a consequence of
screening during the current study.
doi:10.1371/journal.pone.0131777.t002
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transesophageal echocardiography revealed no signs of endocarditis, he was placed on a treat-
ment regimen consisting of doxycycline (200 mg qd) and hydroxychloroquine (200 mg tid).
Of the 69 individuals with known cardiovascular risk factors, 16 (23.2%) were IFA-positive
Table 1; three of the 16 participants previously received the Q-fever vaccine, and the other 13
were exposed to Q-fever naturally. Of these 13 participants two (15.4%) developed a chronic
infection. These were the two participants (out of the six with an IgG I1:512) previously
diagnosed with chronic Q-fever.
Comparison of the 2014 IFA test results with previous Q-fever tests. In 2007, 25.3%
(111/443) of sampled adult inhabitants in Herpen were IFA-positive. We compared results
from 287 individuals who participated in both studies and gave their consent to compare their
data. Of the 204 IFA-seronegative participants in 2007, 36 (17.6%) were IFA seropositive in
2014; these participants presumably became infected after 2007. Of the 83 seropositive partici-
pants in 2007, 14 (16.9%) tested negative in 2014.
Analysis of the data collected from the MHS, microbiological laboratories, and the Herpen
2007 study revealed that 24.9% of the IFA-positive participants in 2014 (N = 128/513) previ-
ously tested positive. Although the laboratories informed the MHS of these 128 infections
(because acute Q-fever is a notifiable disease), 78 (60.9%) of these cases did not meet the
national notification criteria. Of the 513 positive participants in 2014, 51 (9.9%) had been noti-
fied previously by the MHS.
Discussion
Seven years after a national Q-fever outbreak in the Netherlands, screening of 1,517 adults in
one Dutch village revealed 33.8% seropositive participants and six participants with an IgG I
titer1:512. Two of these six participants were previously identified as having chronic Q-
fever. Clinical evaluation of the remaining four individuals revealed one new chronic infection
in a patient who had no prior history of acute Q-fever, no known cardiovascular risk factors,
and no symptoms associated with an acute episode.
Prevalence of Q-fever
To the best of our knowledge, this is the first large-scale seroprevalence study conducted in an
entire village in order to identify patients with chronic Q-fever. The seroprevalence of antibod-
ies against C. burnetii in our study (33.8%) is higher than the 12.2% reported among blood
donors from high-incidence areas [5]. Lower and higher [11] IFA cut-off values are used for
screening. Lacking an international standard we used the value commonly used in the Nether-
lands. Because the village population presumably was exposed to C. burnetii from 2007
through 2010, we expected to find evidence of waning immunity in 2014. Our finding that
16.9% participants seroreverted from IFA-positive to IFA-negative is consistent with a study in
Wales that reported a serorevertion rate of 18% after six years [12]. Thus, our 2014 test results
are likely an underestimation of the actual number of infections that occurred during the
outbreak.
A recent study conducted among blood donors from high-incidence areas concluded that
each notification might actually represent12 infections [13]. In our study, 9.9% of IFA–posi-
tive participants were notified, confirming that the number of infections is approximately ten-
fold greater than the number of notifications. Because these results were obtained from a village
in which both the GPs and the general public are highly aware of Q-fever, we expect that even
more infections went undiagnosed in other regions. Such underreporting is due primarily to
asymptomatic infections, symptomatic but undiagnosed infections, and infections that do not
meet our national notification criteria.
Population Screening for Chronic Q-Fever
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We found that 0.6% of seropositive participants in our study population developed chronic
Q-fever, which is a lower rate than the 1.5–2% reported in the literature [5,6]. Serological test-
ing within one year detects 98% [14] of the patients at risk for developing chronic Q-fever.
However, the incubation time for chronic Q-fever is unknown and without further serological
and clinical investigation can present years or even decades later [15].
Strengths and limitations of the study
The primary strengths of our study are the large sample size, the high response rate (70.2% of
the entire adult population in Herpen), the relative homogeneity of the study population, and
the similarity between participants and non-participants. A limitation of our study is the possi-
bility that individuals developed chronic Q fever earlier and died without being diagnosed. It
cannot be excluded that those with severe disease were unable to participate, moved or also
died since the outbreak. We have no information on non-participants and their Q fever status.
We cannot exclude that one or more non-participants have chronic Q-fever. We cannot
exclude potential bias caused by non-participation. Seropositive individuals could have been
over represented if they desired to know their serological status because of certain risk factors.
On the other hand they could have been under represented as they knew their long-term status
due to serological follow-up. Those with an unknown Q-fever status or with a perceived risk
for example occupational, might have shown increased interest in the study. Furthermore we
could only contact those who were registered by the municipality but we expect the number of
unregistered inhabitants to be very low.
Conclusions
The Q-fever seroprevalence rate found in our study was remarkably high (34%), and 15% of
the infected participants with at least one cardiovascular risk factor developed a chronic infec-
tion. Although our study revealed one new individual with chronic Q-fever, it is unlikely that
screening other communities for chronic infections—particularly communities that were not
as heavily exposed to C.burnetii during the outbreak—would yield significantly more infec-
tions. A policy of screening known high-risk groups for chronic infections in outbreak areas
following an outbreak [8] might be more efficient and should be implemented rather than ad
hoc population screening. A cost-effectiveness analysis should also be performed before initiat-
ing a population screening program for chronic Q-fever.
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S1 Table. IFA test results of 1517 participants. The six potential chronic cases are shown in
bold italics. Positive means a titer1:64. The sample was however not titrated as phase I was
not higher than 1:64. This made titration-in order to detect chronic Q-fever- unnecessary.
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